Funding for effective, ‘less risky’ treatments extended until summer 2021
News
EU approval for new AI technology that can predict heart attacks
CaRi-Heart technology can identify people at high risk of a fatal heart attack
FDA green light for BMS, bluebird bio’s CAR-T therapy Abecma in multiple myeloma
CAR-T therapy cleared for use in adults with relapsed or refractory multiple myeloma
Inctye’s Pemazyre authorised in the EU for bile duct cancer
Kinase inhibitor authorised to treat advanced bile duct cancer patients with a FGFR2 fusion or rearrangement
GSK agrees to support manufacture of Novavax’ COVID-19 vaccine
British drugmaker will help to produce up to 60 million doses for use in the UK
New research project aims to improve understanding of differing decisions on medicine use
Review will collate global information to help identify differences between regions
GSK, Vir Biotech seek emergency use authorisation for COVID-19 antibody
Companies are requesting emergency approval of drug for the early treatment of COVID-19
Novartis UK signs digital partnership with Cievert for chronic disease management
Initiative is aiming to support NHS patient care in rheumatology and dermatology
Five new meds recommended in March CHMP decisions
The committee also recommended six extensions of current therapeutic indications
Researchers identify new genetic clues for ‘silent’ strokes
British Heart Foundation-funded researchers hope findings can aid the development of new treatments
Cancer Research UK launches new ‘cancer tech accelerator’ programme
New initiative aims to help researchers translate their ideas into innovations for cancer patients
EMA accepts Astellas/Seagen’s enfortumab vedotin for review
Marketing authorisation application is seeking approval for advanced urothelial cancer
NHS England makes Keytruda available for advanced colorectal cancer during pandemic
Interim treatment agreement reached for eligible patients during COVID-19 pandemic
Relugolix shows potential long-term benefit in women with uterine fibroids
Study compared women who continued on relugolix combination therapy with women who discontinued treatment
Cambridge start-up PhoreMost raises £33m to progress PLK1 programme
Lead ‘Allosteric PLK1’ asset will initially target brain cancer
